Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Fox04-DRI: Evidence Summary
Evidence summary for Fox04-DRI across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Fox04-DRI overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Senolytic therapy | Tier D | 0 | Disrupts FOXO4-p53 interaction to induce senescent cell apoptosis; mouse data only |
| Anti-aging | Tier D | 0 | Restored fitness and fur density in aged mice; no human trials initiated |